Advertisement

Primary Central Nervous System Lymphoma

  • Panagiotis Papanastasopoulos
  • Mark BowerEmail author
  • Thomas S. Uldrick
Chapter

Abstract

Primary central nervous system lymphoma (PCNSL) is an extra-nodal form of non-Hodgkin’s lymphoma (NHL) that is confined to the cranio-spinal axis without systemic involvement. PCNSL occurs in both immunocompetent and immunodeficient individuals, and the two groups share some features but differ in biology, clinical management and outcomes.

Keywords

Primary Central Nervous System Lymphoma Brain Biopsy Cerebral Toxoplasmosis Cryptococcal Meningoencephalitis Autologous Haematopoietic Stem Cell Transplantation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Snider WD, Simpson DM, Nielsen S, Gold JW, Metroka CE, Posner JB. Neurological complications of acquired immune deficiency syndrome: analysis of 50 patients. Ann Neurol. 1983;14(4):403–18.CrossRefPubMedGoogle Scholar
  2. 2.
    Cote TR, Manns A, Hardy CR, Yellin FJ, Hartge P. Epidemiology of brain lymphoma among people with or without acquired immunodeficiency syndrome. AIDS/Cancer Study Group. J Natl Cancer Inst. 1996;88(10):675–9. Epub 1996/05/15.CrossRefPubMedGoogle Scholar
  3. 3.
    International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst. 2000;92(22):1823–30.CrossRefGoogle Scholar
  4. 4.
    Ammassari A, Cingolani A, Pezzotti P, De Luca DA, Murri R, Giancola ML, et al. AIDS-related focal brain lesions in the era of highly active antiretroviral therapy. Neurology. 2000;55(8):1194–200. Epub 2000/11/09.CrossRefPubMedGoogle Scholar
  5. 5.
    Wolf T, Brodt HR, Fichtlscherer S, Mantzsch K, Hoelzer D, Helm EB, et al. Changing incidence and prognostic factors of survival in AIDS-related non-Hodgkin’s lymphoma in the era of highly active antiretroviral therapy (HAART). Leuk Lymphoma. 2005;46(2):207–15.CrossRefPubMedGoogle Scholar
  6. 6.
    Pipkin S, Scheer S, Okeigwe I, Schwarcz S, Harris DH, Hessol NA. The effect of HAART and calendar period on Kaposi’s sarcoma and non-Hodgkin lymphoma: results of a match between an AIDS and cancer registry. AIDS. 2011;25(4):463–71. Epub 2010/12/09.PubMedCentralCrossRefPubMedGoogle Scholar
  7. 7.
    Bower M, Powles T, Nelson M, Mandalia S, Gazzard B, Stebbing J. Highly active antiretroviral therapy and human immunodeficiency virus-associated primary cerebral lymphoma. J Natl Cancer Inst. 2006;98(15):1088–91. Epub 2006/08/03.CrossRefPubMedGoogle Scholar
  8. 8.
    Olson JE, Janney CA, Rao RD, Cerhan JR, Kurtin PJ, Schiff D, et al. The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis. Cancer. 2002;95(7):1504–10. Epub 2002/09/19.CrossRefPubMedGoogle Scholar
  9. 9.
    Deckert M, Engert A, Bruck W, Ferreri AJ, Finke J, Illerhaus G, et al. Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma. Leukemia. 2011;25(12):1797–807. Epub 2011/08/06.CrossRefPubMedGoogle Scholar
  10. 10.
    Larocca LM, Capello D, Rinelli A, Nori S, Antinori A, Gloghini A, et al. The molecular and phenotypic profile of primary central nervous system lymphoma identifies distinct categories of the disease and is consistent with histogenetic derivation from germinal center-related B cells. Blood. 1998;92(3):1011–9. Epub 1998/07/29.PubMedGoogle Scholar
  11. 11.
    Carbone A, Gaidano G, Gloghini A, Larocca LM, Capello D, Canzonieri V, et al. Differential expression of BCL-6, CD138/syndecan-1, and Epstein-Barr virus-encoded latent membrane protein-1 identifies distinct histogenetic subsets of acquired immunodeficiency syndrome-related non-Hodgkin’s lymphomas. Blood. 1998;91:747–55.PubMedGoogle Scholar
  12. 12.
    Abed N, Casper JT, Camitta BM, Margolis D, Trost B, Orentas R, et al. Evaluation of histogenesis of B-lymphocytes in pediatric EBV-related post-transplant lymphoproliferative disorders. Bone Marrow Transplant. 2004;33(3):321–7. Epub 2003/12/23.CrossRefPubMedGoogle Scholar
  13. 13.
    MacMahon EM, Glass JD, Hayward SD, Mann RB, Becker PS, Charache P, et al. Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. Lancet. 1991;338(8773):969–73.CrossRefPubMedGoogle Scholar
  14. 14.
    Gasser O, Bihl FK, Wolbers M, Loggi E, Steffen I, Hirsch HH, et al. HIV patients developing primary CNS lymphoma lack EBV-specific CD4+ T cell function irrespective of absolute CD4+ T cell counts. PLoS Med. 2007;4(3):e96.PubMedCentralCrossRefPubMedGoogle Scholar
  15. 15.
    Bataille B, Delwail V, Menet E, Vandermarcq P, Ingrand P, Wager M, et al. Primary intracerebral malignant lymphoma: report of 248 cases. J Neurosurg. 2000;92(2):261–6. Epub 2000/02/05.CrossRefPubMedGoogle Scholar
  16. 16.
    Ambinder RF, Lee S, Curran WJ, Sparano JA, Krigel RL, McArthur JC, et al. Phase II intergroup trial of sequential chemotherapy and radiotherapy for AIDS-related primary central nervous system lymphoma. Cancer Ther. 2003;1:215–21.Google Scholar
  17. 17.
    Jacomet C, Girard P, Lebrette M, Farese V, Monfort L, Rozenbaum W. Intravenous methotrexate for primary central nervous system non-Hodgkin’s lymphoma in AIDS. AIDS. 1997;11:1725–30.CrossRefPubMedGoogle Scholar
  18. 18.
    Bower M, Fife K, Sullivan A, Kirk S, Phillips RH, Nelson M, et al. Treatment outcome in presumed and confirmed AIDS-related primary cerebral lymphoma. Eur J Cancer. 1999;35(4):601–4.CrossRefPubMedGoogle Scholar
  19. 19.
    Cheung TW. AIDS-related cancer in the era of highly active antiretroviral therapy (HAART): a model of the interplay of the immune system, virus, and cancer. “On the offensive – the Trojan Horse is being destroyed” – part B: malignant lymphoma. Cancer Invest. 2004;22(5):787–98.CrossRefPubMedGoogle Scholar
  20. 20.
    Morgello S, Petito CK, Mouradian JA. Central nervous system lymphoma in the acquired immunodeficiency syndrome. Clin Neuropathol. 1990;9(4):205–15. Epub 1990/07/01.PubMedGoogle Scholar
  21. 21.
    Chang L, Cornford ME, Chiang FL, Ernst TM, Sun NC, Miller BL. Radiologic-pathologic correlation. Cerebral toxoplasmosis and lymphoma in AIDS. AJNR Am J Neuroradiol. 1995;16(8):1653–63. Epub 1995/09/01.PubMedGoogle Scholar
  22. 22.
    Gildenberg PL, Gathe Jr JC, Kim JH. Stereotactic biopsy of cerebral lesions in AIDS. Clin Infect Dis Off Publ Infect Dis Soc Am. 2000;30(3):491–9. Epub 2000/03/18.CrossRefGoogle Scholar
  23. 23.
    Bakshi R. Neuroimaging of HIV and AIDS related illnesses: a review. Front Biosci J Virtual libr. 2004;9:632–46. Epub 2004/02/10.CrossRefGoogle Scholar
  24. 24.
    Pirotte B, Levivier M, Goldman S, Brucher JM, Brotchi J, Hildebrand J. Glucocorticoid-induced long-term remission in primary cerebral lymphoma: case report and review of the literature. J Neurooncol. 1997;32(1):63–9. Epub 1997/03/01.CrossRefPubMedGoogle Scholar
  25. 25.
    Bashir R, Luka J, Cheloha K, Chamberlain M, Hochberg F. Expression of Epstein-Barr virus proteins in primary CNS lymphoma in AIDS patients. Neurology. 1993;43(11):2358–62. Epub 1993/11/01.CrossRefPubMedGoogle Scholar
  26. 26.
    Cinque P, Brytting M, Vago L, Castagna A, Parravicini C, Zanchetta N, et al. Epstein-Barr virus DNA in cerebrospinal fluid from patients with AIDS-related primary lymphoma of the central nervous system. Lancet. 1993;342:398–401.CrossRefPubMedGoogle Scholar
  27. 27.
    Arribas J, Clifford D, Fichtenbaum C, Roberts R, Powderly W, Storch G. Detection of Epstein-Barr virus DNA in cerebrospinal fluid for diagnosis of AIDS-related central nervous system lymphoma. J Clin Microbiol. 1995;33(6):1580–3.PubMedCentralPubMedGoogle Scholar
  28. 28.
    Bossolasco S, Cinque P, Ponzoni M, Vigano MG, Lazzarin A, Linde A, et al. Epstein-Barr virus DNA load in cerebrospinal fluid and plasma of patients with AIDS-related lymphoma. J Neurovirol. 2002;8(5):432–8. Epub 2002/10/29.CrossRefPubMedGoogle Scholar
  29. 29.
    Ruiz A, Ganz W, Post M, et al. Use of thallium-201 brain SPECT to differentiate cerebral lymphoma from Toxoplasma encephalitis in AIDS patients. AmJ Neuroradiol. 1994;15:1885–94.Google Scholar
  30. 30.
    Lorberboym M, Estok L, Machac J, Germano I, Sacher M, Feldman R, et al. Rapid differential diagnosis of cerebral toxoplasmosis and primary central nervous system lymphoma by thallium-201 SPECT. J Nucl Med. 1996;37(7):1150–4.PubMedGoogle Scholar
  31. 31.
    D’Amico A, Messa C, Castagna A, Zito F, Galli L, Pepe G, et al. Diagnostic accuracy and predictive value of 201T1 SPET for the differential diagnosis of cerebral lesions in AIDS patients. Nucl Med Commun. 1997;18(8):741–50. Epub 1997/08/01.CrossRefPubMedGoogle Scholar
  32. 32.
    Miller RF, Hall-Craggs MA, Costa DC, Brink NS, Scaravilli F, Lucas SB, et al. Magnetic resonance imaging, thallium-201 SPET scanning, and laboratory analyses for discrimination of cerebral lymphoma and toxoplasmosis in AIDS. Sex Transm Infect. 1998;74(4):258–64. Epub 1999/01/30.PubMedCentralCrossRefPubMedGoogle Scholar
  33. 33.
    Lorberboym M, Wallach F, Estok L, Mosesson RE, Sacher M, Kim CK, et al. Thallium-201 retention in focal intracranial lesions for differential diagnosis of primary lymphoma and nonmalignant lesions in AIDS patients. J Nucl Med. 1998;39(8):1366–9. Epub 1998/08/26.PubMedGoogle Scholar
  34. 34.
    Antinori A, De Rossi G, Ammassari A, Cingolani A, Murri R, Di Giuda D, et al. Value of combined approach with thallium-201 single-photon emission computed tomography and Epstein-Barr virus DNA polymerase chain reaction in CSF for the diagnosis of AIDS-related primary CNS lymphoma. J Clin Oncol Off J Am Soc Clin Oncol. 1999;17(2):554–60. Epub 1999/03/18.Google Scholar
  35. 35.
    Skiest DJ, Erdman W, Chang WE, Oz OK, Ware A, Fleckenstein J. SPECT thallium-201 combined with Toxoplasma serology for the presumptive diagnosis of focal central nervous system mass lesions in patients with AIDS. J Infect. 2000;40(3):274–81. Epub 2000/07/25.CrossRefPubMedGoogle Scholar
  36. 36.
    Licho R, Litofsky NS, Senitko M, George M. Inaccuracy of Tl-201 brain SPECT in distinguishing cerebral infections from lymphoma in patients with AIDS. Clin Nucl Med. 2002;27(2):81–6. Epub 2002/01/12.CrossRefPubMedGoogle Scholar
  37. 37.
    Hoffman J, Waskin H, Schifter T, Hanson M, Gray L, Rosenfeld S, et al. FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS. J Nucl Med. 1993;34(4):567–75.PubMedGoogle Scholar
  38. 38.
    Villringer K, Jager H, Dichgans M, Ziegler S, Poppinger J, Herz M, et al. Differential diagnosis of CNS lesions in AIDS patients by FDG-PET. J Comput Assist Tomogr. 1995;19(4):532–6.CrossRefPubMedGoogle Scholar
  39. 39.
    Heald A, Hoffman J, Bartlett J, Waskin H. Differentiation of central nervous system lesions in AIDS patients using positron emission tomography (PET). Int J STD AIDS. 1996;7(5):337–46.CrossRefPubMedGoogle Scholar
  40. 40.
    O’Doherty MJ, Barrington SF, Campbell M, Lowe J, Bradbeer CS. PET scanning and the human immunodeficiency virus-positive patient. J Nucl Med. 1997;38(10):1575–83.PubMedGoogle Scholar
  41. 41.
    Kasamon YL, Ambinder RF. AIDS-related primary central nervous system lymphoma. Hematol Oncol Clin North Am. 2005;19(4):665–87. vi–vii. Epub 2005/08/09.CrossRefPubMedGoogle Scholar
  42. 42.
    Lewitschnig S, Gedela K, Toby M, Kulasegaram R, Nelson M, O’Doherty M, et al. (1)(8)F-FDG PET/CT in HIV-related central nervous system pathology. Eur J Nucl Med Mol Imaging. 2013;40(9):1420–7. Epub 2013/05/21.CrossRefPubMedGoogle Scholar
  43. 43.
    Castagna A, Cinque P, d’Amico A, Messa C, Fazsio F, Lazzarin A. Evaluation of contrast-enhancing brain lesions in AIDS patients by means of Epstein-Barr virus detection in cerebrospinal fluid and 201thallium single photon emission tomography. AIDS. 1997;11:1522–3.PubMedGoogle Scholar
  44. 44.
    Iacoangeli M, Roselli R, Antinori A, Ammassari A, Murri R, Pompucci A, et al. Experience with brain biopsy in acquired immune deficiency syndrome-related focal lesions of the central nervous system. Br J Surg. 1994;81(10):1508–11. Epub 1994/10/01.CrossRefPubMedGoogle Scholar
  45. 45.
    Davies MA, Pell MF, Brew BJ. Stereotactic biopsy of cerebral lesions in acquired immunodeficiency syndrome. J Clin Neurosci Off J Neurosurg Soc Australasia. 1995;2(1):40–4. Epub 1995/01/01.Google Scholar
  46. 46.
    Luzzati R, Ferrari S, Nicolato A, Piovan E, Malena M, Merighi M, et al. Stereotactic brain biopsy in human immunodeficiency virus-infected patients. Arch Intern Med. 1996;156(5):565–8. Epub 1996/03/11.CrossRefPubMedGoogle Scholar
  47. 47.
    Skolasky RL, Dal Pan GJ, Olivi A, Lenz FA, Abrams RA, McArthur JC. HIV-associated primary CNS lymorbidity and utility of brain biopsy. J Neurol Sci. 1999;163(1):32–8. Epub 1999/05/01.CrossRefPubMedGoogle Scholar
  48. 48.
    Hoffmann C, Tabrizian S, Wolf E, Eggers C, Stoehr A, Plettenberg A, et al. Survival of AIDS patients with primary central nervous system lymphoma is dramatically improved by HAART-induced immune recovery. AIDS. 2001;15(16):2119–27.CrossRefPubMedGoogle Scholar
  49. 49.
    Skiest DJ, Crosby C. Survival is prolonged by highly active antiretroviral therapy in AIDS patients with primary central nervous system lymphoma. AIDS. 2003;17(12):1787–93.CrossRefPubMedGoogle Scholar
  50. 50.
    Newell ME, Hoy JF, Cooper SG, DeGraaff B, Grulich AE, Bryant M, et al. Human immunodeficiency virus-related primary central nervous system lymphoma: factors influencing survival in 111 patients. Cancer. 2004;100(12):2627–36.CrossRefPubMedGoogle Scholar
  51. 51.
    Diamond C, Taylor TH, Im T, Miradi M, Wallace M, Anton-Culver H. Highly active antiretroviral therapy is associated with improved survival among patients with AIDS-related primary central nervous system non-Hodgkin’s lymphoma. Curr HIV Res. 2006;4(3):375–8. Epub 2006/07/18.CrossRefPubMedGoogle Scholar
  52. 52.
    Bayraktar S, Bayraktar UD, Ramos JC, Stefanovic A, Lossos IS. Primary CNS lymphoma in HIV positive and negative patients: comparison of clinical characteristics, outcome and prognostic factors. J Neurooncol. 2011;101(2):257–65. Epub 2010/06/08.CrossRefPubMedGoogle Scholar
  53. 53.
    Achenbach CJ, Cole SR, Kitahata MM, Casper C, Willig JH, Mugavero MJ, et al. Mortality after cancer diagnosis in HIV-infected individuals treated with antiretroviral therapy. AIDS. 2011;25(5):691–700. Epub 2010/12/17.PubMedCentralCrossRefPubMedGoogle Scholar
  54. 54.
    Norden AD, Drappatz J, Wen PY, Claus EB. Survival among patients with primary central nervous system lymphoma, 1973–2004. J Neurooncol. 2011;101(3):487–93. Epub 2010/06/18.CrossRefPubMedGoogle Scholar
  55. 55.
    Uldrick TS, Pipkin S, Scheer S, Hessol NA. Factors associated with survival among patients with AIDS-related primary central nervous system lymphoma. AIDS. 2014;28(3):397–405. Epub 2013/10/01.PubMedCentralCrossRefPubMedGoogle Scholar
  56. 56.
    Gopal S, Patel MR, Yanik EL, Cole SR, Achenbach CJ, Napravnik S, et al. Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era. J Natl Cancer Inst. 2013;105(16):1221–9. Epub 2013/07/31.PubMedCentralCrossRefPubMedGoogle Scholar
  57. 57.
    Aboulafia DM, Puswella AL. Highly active antiretroviral therapy as the sole treatment for AIDS-related primary central nervous system lymphoma: a case report with implications for treatment. AIDS Patient Care STDS. 2007;21(12):900–7. Epub 2007/12/25.CrossRefPubMedGoogle Scholar
  58. 58.
    Chamberlain MC, Kormanik PA. AIDS-related central nervous system lymphomas. J Neurooncol. 1999;43(3):269–76. Epub 1999/11/24.CrossRefPubMedGoogle Scholar
  59. 59.
    Nelson DF, Martz KL, Bonner H, Nelson JS, Newall J, Kerman HD, et al. Non-Hodgkin’s lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys. 1992;23(1):9–17. Epub 1992/01/01.CrossRefPubMedGoogle Scholar
  60. 60.
    Baumgartner JE, Rachlin JR, Beckstead JH, Meeker TC, Levy RM, Wara WM, et al. Primary central nervous system lymphomas: natural history and response to radiation therapy in 55 patients with acquired immunodeficiency syndrome. J Neurosurg. 1990;73(2):206–11. Epub 1990/08/01.CrossRefPubMedGoogle Scholar
  61. 61.
    Donahue B, Sullivan J, Cooper J. Additional experience with empiric radiotherapy for presumed human immunodeficiency virus-associated primary central nervous system lymphoma. Cancer. 1995;76:328–32.CrossRefPubMedGoogle Scholar
  62. 62.
    Nagai H, Odawara T, Ajisawa A, Tanuma J, Hagiwara S, Watanabe T, et al. Whole brain radiation alone produces favourable outcomes for AIDS-related primary central nervous system lymphoma in the HAART era. Eur J Haematol. 2010;84(6):499–505. Epub 2010/02/06.CrossRefPubMedGoogle Scholar
  63. 63.
    Forsyth PA, Yahalom J, DeAngelis LM. Combined-modality therapy in the treatment of primary central nervous system lymphoma in AIDS. Neurology. 1994;44(8):1473–9. Epub 1994/08/01.CrossRefPubMedGoogle Scholar
  64. 64.
    Raez L, Cabral L, Cai JP, Landy H, Sfakianakis G, Byrne Jr GE, et al. Treatment of AIDS-related primary central nervous system lymphoma with zidovudine, ganciclovir, and interleukin 2. AIDS Res Hum Retroviruses. 1999;15(8):713–9. Epub 1999/06/05.CrossRefPubMedGoogle Scholar
  65. 65.
    Aboulafia DM, Ratner L, Miles SA, Harrington Jr WJ. Antiviral and immunomodulatory treatment for AIDS-related primary central nervous system lymphoma: AIDS Malignancies Consortium pilot study 019. Clin Lymphoma Myeloma. 2006;6(5):399–402. Epub 2006/04/28.CrossRefPubMedGoogle Scholar
  66. 66.
    Bossolasco S, Falk KI, Ponzoni M, Ceserani N, Crippa F, Lazzarin A, et al. Ganciclovir is associated with low or undetectable Epstein-Barr virus DNA load in cerebrospinal fluid of patients with HIV-related primary central nervous system lymphoma. Clin Infect Dis Off Publ Infect Dis Soc Am. 2006;42(4):e21–5. Epub 2006/01/20.CrossRefGoogle Scholar
  67. 67.
    DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol. 2002;20(24):4643–8. Epub 2002/12/19.CrossRefPubMedGoogle Scholar
  68. 68.
    Ferreri AJ, Reni M, Foppoli M, Martelli M, Pangalis GA, Frezzato M, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet. 2009;374(9700):1512–20. Epub 2009/09/22.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  • Panagiotis Papanastasopoulos
    • 1
  • Mark Bower
    • 1
    • 2
    Email author
  • Thomas S. Uldrick
    • 3
  1. 1.National Centre for HIV MalignancyChelsea and Westminster HospitalLondonUK
  2. 2.Department of OncologyChelsea and Westminster HospitalLondonUK
  3. 3.HIV and AIDS Malignancy BranchCenter for Cancer Research, NCIBethesdaUSA

Personalised recommendations